PMC6029461_01
Course of norepinephrine and epinephrine demand during Cytosorb treatment in all treated patients. Values are shown at the beginning of the treatment and after every treatment until the end.
CRICC2018-1205613.001.jpg
PMC6029461_04_CRICC2018-1205613.001.jpg
fig1
The course of norepinephrine is shown in Figure 1.
Course of lactate and PCT during Cytosorb treatment in all treated patients. PCT is not presented for Case 5 because it has not been measured with routine. Values are shown at the beginning of the treatment and after every treatment until the end.
CRICC2018-1205613.002.jpg
PMC6029461_04_CRICC2018-1205613.002.jpg
fig2
The patient showed a stabilization lactate level, reduced at 1.7 mmol/l, as presented in Figure 2.
PMC6029461_02
Course of norepinephrine and epinephrine demand during Cytosorb treatment in all treated patients. Values are shown at the beginning of the treatment and after every treatment until the end.
CRICC2018-1205613.001.jpg
PMC6029461_04_CRICC2018-1205613.001.jpg
fig1
The course of norepinephrine is shown in Figure 1.
Course of lactate and PCT during Cytosorb treatment in all treated patients. PCT is not presented for Case 5 because it has not been measured with routine. Values are shown at the beginning of the treatment and after every treatment until the end.
CRICC2018-1205613.002.jpg
PMC6029461_04_CRICC2018-1205613.002.jpg
fig2
The patient showed a stabilization lactate level, reduced at 1.7 mmol/l, as presented in Figure 2.
PMC6029461_03
Course of norepinephrine and epinephrine demand during Cytosorb treatment in all treated patients. Values are shown at the beginning of the treatment and after every treatment until the end.
CRICC2018-1205613.001.jpg
PMC6029461_04_CRICC2018-1205613.001.jpg
fig1
The course of norepinephrine is shown in Figure 1.
Course of lactate and PCT during Cytosorb treatment in all treated patients. PCT is not presented for Case 5 because it has not been measured with routine. Values are shown at the beginning of the treatment and after every treatment until the end.
CRICC2018-1205613.002.jpg
PMC6029461_04_CRICC2018-1205613.002.jpg
fig2
The patient showed a stabilization lactate level, reduced at 1.7 mmol/l, as presented in Figure 2.
PMC6029461_04
Course of norepinephrine and epinephrine demand during Cytosorb treatment in all treated patients. Values are shown at the beginning of the treatment and after every treatment until the end.
CRICC2018-1205613.001.jpg
PMC6029461_04_CRICC2018-1205613.001.jpg
fig1
The course of norepinephrine is shown in Figure 1.
Course of lactate and PCT during Cytosorb treatment in all treated patients. PCT is not presented for Case 5 because it has not been measured with routine. Values are shown at the beginning of the treatment and after every treatment until the end.
CRICC2018-1205613.002.jpg
PMC6029461_04_CRICC2018-1205613.002.jpg
fig2
The patient showed a stabilization lactate level, reduced at 1.7 mmol/l, as presented in Figure 2.
Course of IL-6 during Cytosorb treatment in Case 5. Values are shown after the first Cytosorb treatment, and then after every 24h until the end.
CRICC2018-1205613.003.jpg
PMC6029461_04_CRICC2018-1205613.003.jpg
fig3
Moreover, the inflammatory status was also monitored during Cytosorb treatment dosing IL-6 levels (Figure 3), directly adsorbed by the sorbent.